Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06319248 · ClinicalTrials.gov registry record · Phase 2
MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial
A Phase 2 study of Sepsis and Low Blood Pressure, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 308
- Enrollment target
- 1
- Study location
NCT06319248: Recruiting Phase 2 study of Sepsis and Low Blood Pressure, sponsored by Mayo Clinic.
NCT06319248 is a Phase 2 study of Sepsis and Low Blood Pressure that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 308 participants, below the 6,561-participant average among 90 other Sepsis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06319248, a Phase 2 study of Sepsis and Low Blood Pressure, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 308 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to determine if early administration of Midodrine can improve outcomes by maintaining a higher mean blood pressure off of intravenous medications. Researchers want to see if Midodrine can help people with sepsis need fewer vasopressors, which could mean shorter hospital stays, less time with uncomfortable tubes, and a smoother recovery overall.
Primary Outcome
Measured in hours
Conditions Studied
Interventions
- OTHER Standard of Care
- DRUG Midodrine
Study Locations (1)
Minnesota
- Mayo Clinic Minnesota - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2024-05-14 |
| Est. Completion | 2029-07-30 |
| Phase | Phase 2 |
What NCT06319248 shows while recruiting
NCT06319248 is an interventional study that assigns participants to a tested intervention. The registered 308 participants enrollment target is mid-sized for trials with a published cap, below the 6,561-participant average among 90 other Sepsis trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Sepsis appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT06319248 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06319248 about?
NCT06319248 is a clinical study titled "MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial". This study is being done to determine if early administration of Midodrine can improve outcomes by maintaining a higher mean blood pressure off of intravenous medications. Researchers want to see if Midodrine can help people with sepsis need fewer vasopressors, which could mean shorter hospital stay...
What is the current status of trial NCT06319248?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 308 participants. The study started on 2024-05-14. Estimated completion is 2029-07-30.
What conditions does trial NCT06319248 study?
This clinical trial studies the following conditions: Sepsis, Low Blood Pressure.
What interventions are being tested in trial NCT06319248?
The interventions under investigation include: Standard of Care (OTHER), Midodrine (DRUG).
Who is sponsoring clinical trial NCT06319248?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06319248 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06319248's enrollment target sits among peer trials
308 33rd of 90 higher than 58 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
RECRUITING · Phase 2
-
An Acupuncture Study for People At High Risk for Sepsis
RECRUITING · Phase 2
-
Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection
COMPLETED · Phase 2
-
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
COMPLETED · Phase 2
-
Inulin for Infections in the Intensive Care Unit
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04162938 · 308 participants · NA
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
- NCT04955795 · 308 participants · NA
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
- NCT06090539 · 308 participants · Phase 1
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
- NCT06233942 · 308 participants · Phase 1
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI